Curcumin Inhibits Pro-survival Pathways in CLL B-cells and has the Potential to Overcome Stromal Protection of CLL B-cells in Combination with EGCG

od Ghosh, Asish K., Kay, Neil E., Secreto, Charla R., Shanafelt, Tait D.
Izdano 2009

Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression

od Ghosh, Asish K., Secreto, Charla R., Knox, Traci R., Ding, Wei, Mukhopadhyay, Debabrata, Kay, Neil E.
Izdano 2010

Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Patients

od Manso, Bryce A., Zhang, Henan, Mikkelson, Molly G., Gwin, Kimberly A., Secreto, Charla R., Ding, Wei, Parikh, Sameer A., Kay, Neil E., Medina, Kay L.
izdano v Leukemia (2018)

Direct and Complement Dependent Cytotoxicity in CLL Cells from Patients with High Risk Early Stage Chronic Lymphocytic Leukemia (CLL) Treated with Alemtuzumab and Rituximab

od Zent, Clive S., Secreto, Charla R., LaPlant, Betsy R., Bone, Nancy D., Call, Timothy G., Shanafelt, Tait D., Jelinek, Diane F., Tschumper, Renee C., Kay, Neil E.
Izdano 2008

Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia

od Ojha, Juhi, Secreto, Charla R., Rabe, Kari G., Van Dyke, Daniel L., Kortum, Klaus M., Slager, Susan L., Shanafelt, Tait D., Fonseca, Rafael, Kay, Neil E., Braggio, Esteban
izdano v Br J Haematol (2014)

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab

od Zent, Clive S., Call, Timothy G., Shanafelt, Tait D., Tschumper, Renee T., Jelinek, Diane F., Bowen, Deborah A., Secreto, Charla R., LaPlant, Betsy R., Kabat, Brian F., Kay, Neil E.
Izdano 2008

Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance

od Sinha, Sutapa, Secreto, Charla R., Boysen, Justin C., Lesnick, Connie, Wang, Zhiquan, Ding, Wei, Call, Timothy G., Kenderian, Saad J., Parikh, Sameer A., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
izdano v Blood Cancer J (2021)

Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

od Shanafelt, Tait D., Call, Tim G., Zent, Clive S., LaPlant, Betsy, Bowen, Deborah A., Roos, Michelle, Secreto, Charla R., Ghosh, Asish K., Kabat, Brian F., Lee, Mao-Jung, Yang, Chung S., Jelinek, Diane F., Erlichman, Charles, Kay, Neil E.
Izdano 2009

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

od Sinha, Sutapa, Boysen, Justin C., Chaffee, Kari G., Kabat, Brian F., Slager, Susan L., Parikh, Sameer A., Secreto, Charla R., Call, Tim, Shanafelt, Tait D., Leis, Jose F., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
izdano v Oncotarget (2018)

Bi-directional Activation between Mesenchymal Stem Cells and CLL B-Cells: Implication for CLL Disease Progression

od Ding, Wei, Nowakowski, Grzegorz S., Knox, Traci R., Boysen, Justin C., Maas, Mary L., Schwager, Susan M., Wu, Wenting, Wellik, Linda E., Dietz, Allan B., Ghosh, Asish K., Secreto, Charla R., Medina, Kay L., Shanafelt, Tait D., Zent, Clive S., Call, Timothy G., Kay, Neil E.
Izdano 2009

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

od Awan, Farrukh T., Kay, Neil E., Davis, Melanie E., Wu, Wenting, Geyer, Susan M., Leung, Nelson, Jelinek, Diane F., Tschumper, Renee C., Secreto, Charla R., Lin, Thomas S., Grever, Michael R., Shanafelt, Tait D., Zent, Clive S., Call, Timothy G., Heerema, Nyla A., Lozanski, Gerard, Byrd, John C., Lucas, David M.
Izdano 2009

Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome

od Wang, Yucai, Sinha, Sutapa, Wellik, Linda E., Secreto, Charla R., Rech, Karen L., Call, Timothy G., Parikh, Sameer A., Kenderian, Saad S., Muchtar, Eli, Hayman, Suzanne R., Koehler, Amber B., Van Dyke, Daniel L., Leis, Jose F., Slager, Susan L., Dong, Haidong, Kay, Neil E., He, Rong, Ding, Wei
izdano v Blood Cancer J (2021)

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

od Ding, Wei, LaPlant, Betsy R., Call, Timothy G., Parikh, Sameer A., Leis, Jose F., He, Rong, Shanafelt, Tait D., Sinha, Sutapa, Le-Rademacher, Jennifer, Feldman, Andrew L., Habermann, Thomas M., Witzig, Thomas E., Wiseman, Gregory A., Lin, Yi, Asmus, Erik, Nowakowski, Grzegorz S., Conte, Michael J., Bowen, Deborah A., Aitken, Casey N., Van Dyke, Daniel L., Greipp, Patricia T., Liu, Xin, Wu, Xiaosheng, Zhang, Henan, Secreto, Charla R., Tian, Shulan, Braggio, Esteban, Wellik, Linda E., Micallef, Ivana, Viswanatha, David S., Yan, Huihuang, Chanan-Khan, Asher A., Kay, Neil E., Dong, Haidong, Ansell, Stephen M.
izdano v Blood (2017)